Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nurandociguat - Bayer

Next Previous
Drug Profile

Nurandociguat - Bayer

Alternative Names: BAY-3283142; sGC Activator 4 - Bayer

Latest Information Update: 16 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Antihypertensives; Cardiovascular therapies; Hepatoprotectants; Urologics
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal failure
  • Phase I Cardiovascular disorders; Diabetic retinopathy; Hypertension; Liver disorders

Most Recent Events

  • 16 Sep 2025 (CTIS2024-510856-11-00) (EudraCT2024-510856-11-00): Trial initiation and completion info added; updated DevT; Corrected intro to match DevT as most of the info about indication and countries missing
  • 28 May 2025 No recent reports of development identified for phase-I development in Renal-failure(In volunteers, In adults) in Japan (PO, Immediate release)
  • 01 Apr 2025 Bayer completes a phase-I clinical trials in Cardiovascular disorders (In volunteers) in Netherlands (PO) (CTIS2024-510856-11-00) (EudraCT2024-510856-11-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top